Glucose Injection (Baxter)

Country: New Zealand

Language: English

Source: Medsafe (Medicines Safety Authority)

Active ingredient:

Glucose monohydrate 70%

Available from:

Baxter Healthcare Ltd

INN (International Name):

Glucose monohydrate 70%

Dosage:

70 %

Pharmaceutical form:

Solution for infusion

Composition:

Active: Glucose monohydrate 70%

Units in package:

Bag, plastic, 500 mL

Class:

General sale

Prescription type:

General sale

Manufactured by:

Baxter Healthcare Corporation

Therapeutic indications:

Hypertonic infusion solutions are indicated: - As a source of energy incorporated with parenteral nutrition with minimal dilution effect - For use with an appropriate protein (nitrogen) source in the prevention of nitrogen loss or in the treatment of negative nitrogen balance in patients where: a) The alimentary tract cannot or should not be used b) Gastrointestinal absorption of protein is impaired c) Metabolic requirements for protein are substantially increased, as with extensive burns.

Product summary:

Package - Contents - Shelf Life: Bag, plastic, - 500 mL - 24 months from date of manufacture stored at or below 30°C

Authorization date:

1977-09-06

Summary of Product characteristics

NEW ZEALAND DATA SHEET
Glucose (Viaflex) Data Sheet 26 September 2019
Page 1 of 14
Baxter Healthcare Ltd
1 GLUCOSE INJECTION (BAXTER), (solution for infusion)
GLUCOSE Injection (Baxter)
5% solution for infusion
Glucose Injection (Baxter)
10% solution for infusion
Glucose Injection (Baxter)
25% solution for infusion
Glucose Injection (Baxter)
50% solution for infusion
Glucose Injection (Baxter)
70% solution for infusion
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
_Active ingredient _
The active ingredient is glucose (monohydrate).
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Solution for infusion.
Glucose Injection (Baxter) are clear slightly coloured solutions for
intravenous (IV) infusion, in a
Viaflex® plastic bag.
The Glucose Injection (Baxter) infusion preparations are sterile,
non‐pyrogenic parenteral solutions.
They do not contain an antimicrobial agent or added buffer, and have a
pH of 3.5 ‐ 6.5 for 5% to 25%
glucose
concentrations,
and
a
pH
of
3.2
–
6.5
for
50%
to
70%
glucose
concentrations.
The
concentrations of glucose dissolved in a litre of Water for Injections
and their isotonicity are shown in
Tables 1 and 2 (see section 6.5).
The Glucose Injection (Baxter) 5% infusion is an _isotonic_ solution,
whereas Glucose Injection (Baxter)

10% infusions are _hypertonic_.
4 CLINICAL PARTICULARS
4.1
Therapeutic indications
Isotonic (Glucose Injection (Baxter) 5%) infusion solutions are mainly
indicated:

Whenever non‐electrolyte fluid replacement is required

As a vehicle for drug delivery, provided that the added components are
compatible with glucose.
Hypertonic (Glucose Injection (Baxter)

10%) infusion solutions are indicated:

As a source of energy incorporated with parenteral nutrition with
minimal dilution effect

For use with an appropriate protein (nitrogen) source in the
prevention of nitrogen loss or in the
treatment of negative nitrogen balance in patients where:
a)
the alimentary tract cannot or should not be used
b)
gastrointestinal absorption